Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol for contraception and control of menstrual symptoms

Bibliography

• Edelman A, Gallo MF, Nichols MD, et al. Continuous versus cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials. Hum Reprod 2006;21:573-8
   PubMed Web of Science ®Google Scholar
• Kaunitz AM. Menstruation: choosing whether...and when. Contraception 2000;62:277-84
   PubMed Web of Science ®Google Scholar
• Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 1996;54:71-7
   PubMed Web of Science ®Google Scholar
• Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95:261-6
   PubMed Web of Science ®Google Scholar
• Glasier AF, Smith KB, van der Spuy ZM, et al. Amenorrhea associated with contraception – an international study on acceptability. Contraception 2003;67:1-8
   PubMed Web of Science ®Google Scholar
• Edelman A, Lew R, Cwiak C, et al. Acceptability of contraceptive-induced amenorrhea in a racially diverse group of US women. Contraception 2007;75:450-3
   PubMed Web of Science ®Google Scholar
• Mosher WD, Martinez GM, Chandra A, et al. Use of contraception and use of family planning services in the United States: 1982 – 2002. Adv Data 2004:1-36
   PubMedGoogle Scholar
• Rosenberg MJ, Burnhill MS, Waugh MS, et al. Compliance and oral contraceptives: a review. Contraception 1995;52:137-41
   PubMed Web of Science ®Google Scholar
• Jensen JT, Speroff L. Health benefits of oral contraceptives. Obstet Gynecol Clin North Am 2000;27:705-21
   PubMed Web of Science ®Google Scholar
• Marks L. Sexual Chemistry: a history of the contraceptive pill. New Haven: Yale University Press; 2001
   Google Scholar
• Combination oral contraceptive use and the risk of endometrial cancer. The cancer and steroid hormone study of the centers for disease control and the national institute of child health and human development. JAMA 1987;257:796-800
   PubMedGoogle Scholar
• Chandra A, Martinez GM, Mosher WD, et al. Fertility, family planning, and reproductive health of US women: data from the 2002 National Survey of Family Growth. Vital Health Stat 2005;23:1-160
   Google Scholar
• Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol 1999;181:1263-9
   PubMed Web of Science ®Google Scholar
• Lanes SF, Birmann B, Walker AM, Singer S. Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol 1992;166:956-61
   PubMed Web of Science ®Google Scholar
• Holt VL, Daling JR, McKnight B, et al. Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives. Obstet Gynecol 1992;79:529-33
   PubMed Web of Science ®Google Scholar
• Gallo MF, Nanda K, Grimes DA, Schulz KF. Twenty micrograms vs. > 20 microg estrogen oral contraceptives for contraception: systematic review of randomized controlled trials. Contraception 2005;71:162-9
   PubMed Web of Science ®Google Scholar
• Darney PD. OC practice guidelines: minimizing side effects. Int J Fertil Womens Med 1997;(Suppl 1):158-69
   PubMedGoogle Scholar
• Curtis KM, Hillis SD, Kieke BA Jr, et al. Visits to emergency departments for gynecologic disorders in the United States, 1992 – 1994. Obstet Gynecol 1998;91:1007-12
   PubMedGoogle Scholar
• Vuorma S, Teperi J, Aalto AM, et al. A randomized trial among women with heavy menstruation – impact of a decision aid on treatment outcomes and costs. Health Expect 2004;7:327-37
   PubMed Web of Science ®Google Scholar
• Dawood MY. Ibuprofen and dysmenorrhea. Am J Med 1984;77:87-94
   PubMed Web of Science ®Google Scholar
• Borenstein J, Chiou CF, Dean B, et al. Estimating direct and indirect costs of premenstrual syndrome. J Occup Environ Med 2005;47:26-33
   PubMed Web of Science ®Google Scholar
• Coffee AL, Sulak PJ, Kuehl TJ. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 2007;75:444-9
   PubMed Web of Science ®Google Scholar
• Kwiecien M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception 2003;67:9-13
   PubMed Web of Science ®Google Scholar
• Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002;186:1142-9
   PubMed Web of Science ®Google Scholar
• Andrist LC. Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception 2006;74:174
   PubMedGoogle Scholar
• den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 1999;59:357-62
   PubMedGoogle Scholar
• Shakespeare J, Neve E, Hodder K. Is norethisterone a lifestyle drug? Results of database analysis. BMJ 2000;320:291
   PubMedGoogle Scholar
• Loudon NB, Foxwell M, Potts DM, et al. Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cycle pill regimen. BMJ 1977;2:487-90
   PubMed Web of Science ®Google Scholar
• Falsetti L, Galbignani E. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome. Contraception 1990;42:611-9
   PubMed Web of Science ®Google Scholar
• Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 2003;101:653-61
   PubMed Web of Science ®Google Scholar
• Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003;68:89-96
   PubMed Web of Science ®Google Scholar
• Teichmann AT, Kluft C, Grubb GS, et al. Comparative trial of continuous-use and 21-day cyclic levonorgestrel and ethinyl estradiol oral contraceptive. Obstet Gynecol 2006;107:1
   Google Scholar
• Archer DF, Jensen JT, Johnson JV, et al. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 2006;74:439-45
   PubMed Web of Science ®Google Scholar
• Back DJ, Killick SR, Stevenson PJ, et al. The relative bioavailability of levonorgestrel and ethinylestradiol when administered in tablet and capsule form. Contraception 1987;36:321-6
   PubMed Web of Science ®Google Scholar
• Back DJ, Bates M, Breckenridge AM, et al. The pharmacokinetics of levonorgestrel and ethynylestradiol in women – studies with Ovran and Ovranette. Contraception 1981;23:229-39
   PubMed Web of Science ®Google Scholar
• Endrikat J, Blode H, Gerlinger C, Rosenbaum P, Kuhnz W. A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel. Eur J Contracept Reprod Health Care 2002;7:79-90
   PubMed Web of Science ®Google Scholar
• Fotherby K. Intrasubject variability in the pharmacokinetics of ethynyloestradiol. J Steroid Biochem Mol Biol 1991;38:733-6
   PubMedGoogle Scholar
• Fotherby K. Levonorgestrel. Clinical pharmacokinetics. Clin Pharmacokinet 1995;28:203-15
   PubMed Web of Science ®Google Scholar
• Carol W, Klinger G, Jager R, et al. Pharmacokinetics of ethinylestradiol and levonorgestrel after administration of two oral contraceptive preparations. Exp Clin Endocrinol 1992;99:12-7
   PubMedGoogle Scholar
• Stanczyk FZ, Roy S. Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. Contraception 1990;42:67-96
   PubMed Web of Science ®Google Scholar
• Goldzieher JW. Pharmacology of contraceptive steroids: a brief review. Am J Obstet Gynecol 1989;160:1260-4
   PubMed Web of Science ®Google Scholar
• Gommaa AA, Osman FH. Influence of acetaminophen-induced hepatic necrosis on the pharmacokinetics of levonorgestrel. Contraception 1983;28:149-57
   PubMed Web of Science ®Google Scholar
• Belsey EM. Menstrual bleeding patterns in untreated women and with long-acting methods of contraception. Task force on long-acting systemic agents for fertility regulation. Adv Contracept 1991;7:257-70
   PubMedGoogle Scholar
• Johnson JV, Grubb GS, Constantine GD. Endometrial histology following 1 year of a continuous daily regimen of levonorgestrel 90 micro g/ethinyl estradiol 20 micro g. Contraception 2007;75:23-6
   PubMed Web of Science ®Google Scholar
• Teichmann AT, Kluft C, Grubb G, et al. Comparative trial of continuous-use and 21-day cyclic levonorgestrel and ethinyl estradiol oral contraceptive. Obstet Gynecol 2006;107:12S-a
   Google Scholar
• Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe). Contraception 2007;75:16-22
   PubMed Web of Science ®Google Scholar
• Haspels AA. Clinical experience with a low-dose contraceptive agent. European studies. J Reprod Med 1983;28:71-6
   PubMedGoogle Scholar
• Bachmann G, Sulak PJ, Sampson-Landers C, et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception 2004;70:191-8
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA) Guidance for industry: labeling for combined oral contraceptives, draft guidance. Revision 1. FDA, Rockville, MD, 2004. Available from: http://www.fda.gov/cder/guidance/5197dft.pdf [Accessed October 30 2007]
   Google Scholar
• Shortridge E, Miller K. Contraindications to oral contraceptive use among women in the United States, 1999 – 2001. Contraception 2007;75:355-60
   PubMedGoogle Scholar
• Stang A, Schwingl P, Rivera R. New contraceptive eligibility checklists for provision of combined oral contraceptives and depot-medroxyprogesterone acetate in community-based programmes. Bull World Health Organ 2000;78:1015-23
   PubMed Web of Science ®Google Scholar
• Bladbjerg EM, Skouby SO, Andersen LF, Jespersen J. Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. Hum Reprod 2002;17:3235-41
   PubMed Web of Science ®Google Scholar
• Archer DF. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause 2001;8:245-51
   PubMed Web of Science ®Google Scholar
• Porch JV, Lee IM, Cook NR, et al. Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control 2002;13:847-54
   PubMed Web of Science ®Google Scholar
• Rosenberg M, Waugh MS. Causes and consequences of oral contraceptive noncompliance. Am J Obstet Gynecol 1999;180:276-9
   PubMed Web of Science ®Google Scholar
• Edelman AB, Koontz SL, Nichols MD, Jensen JT. Continuous oral contraceptives: are bleeding patterns dependent on the hormones given? Obstet Gynecol 2006;107:657-65
   PubMed Web of Science ®Google Scholar
• Robinson JC, Plichta S, Weisman CS, et al. Dysmenorrhea and use of oral contraceptives in adolescent women attending a family planning clinic. Am J Obstet Gynecol 1992;166:578-83
   PubMed Web of Science ®Google Scholar